发布文献求助

执着大山

Lv5

880 积分 2025-09-18 加入

最近求助
最近应助
互助留言

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative, Locally Advanced or Metastatic Breast Cancer 2个月前 已关闭
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma 4个月前 已完结
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma 4个月前 已关闭
Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma 4个月前 已关闭
Comprehensive analysis of adverse events associated with T-cell engagers using the FAERS database 4个月前 已完结
Effect of treatment of postmenopausal osteoporosis with continuous daily oral alendronate and the incidence of fractures 4个月前 已关闭
Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120) 5个月前 已完结
Efficacy and safety of rituximab in patients with lupus nephritis: A systematic review and meta-analysis 5个月前 已完结

no response【积分已退回】 2个月前
incorrect doi 10.1200/JCO.24.00427 2个月前

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通